Clinical Trial

A Single-arm, Multicenter Exploratory Clinical Trial of Anlotinib Combined With TQB2450 and the SOX Regimen as First-line Treatment for Advanced Gastric Cancer With Low PD-L1 Expression

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated April 7, 2026 (before its estimated June 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
To evaluate the efficacy and safety of anlotinib combined with TQB2450 and the SOX regimen as first-line treatment for advanced gastric cancer with low PD-L1 expression
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-15.
Status change: Recruiting → Active, Not Recruiting 2026-04-06
Trial Details
NCT Number NCT06939452
Lead Sponsor Yongxu Jia
Conditions Advanced Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
Enrollment 37 participants
Start Date 2023-06-07
Primary Completion 2026-06-01 (estimated)
Study Completion 2026-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-07